Sionna Therapeutics’ (SION) Hold Rating Reiterated at Stifel Nicolaus

Stifel Nicolaus reaffirmed their hold rating on shares of Sionna Therapeutics (NASDAQ:SION) in a research note published on Monday, MarketBeat reports. The firm currently has a $7.00 price objective on the stock.

A number of other equities research analysts have also weighed in on SION. Wedbush began coverage on Sionna Therapeutics in a research report on Tuesday, May 5th. They set an “outperform” rating and a $53.00 price objective on the stock. JonesTrading lifted their price target on Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. Raymond James Financial restated a “market perform” rating and set a $59.00 price target on shares of Sionna Therapeutics in a report on Thursday, August 6th. Guggenheim upped their price objective on Sionna Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Wednesday, August 5th. One analyst has rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $42.22.

Sionna Therapeutics Price Performance

Shares of Sionna Therapeutics stock opened at $6.25 on Monday. The company’s 50 day moving average price is $40.38 and its two-hundred day moving average price is $39.67. The firm has a market capitalization of $282.56 million, a P/E ratio of -2.87 and a beta of 1.33. Sionna Therapeutics has a fifty-two week low of $4.01 and a fifty-two week high of $54.97.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.02). On average, analysts expect that Sionna Therapeutics will post -2.65 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Peter A. Thompson sold 85,918 shares of the stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total value of $3,854,281.48. Following the completion of the sale, the director owned 2,469,959 shares of the company’s stock, valued at approximately $110,802,360.74. This represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 85,918 shares of the stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total value of $3,854,281.48. Following the completion of the sale, the director directly owned 2,469,959 shares of the company’s stock, valued at approximately $110,802,360.74. The trade was a 3.36% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 403,726 shares of company stock valued at $18,259,354 over the last 90 days. 5.10% of the stock is currently owned by company insiders.

Institutional Trading of Sionna Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. bought a new position in Sionna Therapeutics during the 3rd quarter worth approximately $30,000. BNP Paribas Financial Markets bought a new stake in shares of Sionna Therapeutics in the 2nd quarter valued at $31,000. State of Wyoming acquired a new stake in shares of Sionna Therapeutics during the second quarter worth $35,000. GF Fund Management CO. LTD. acquired a new stake in shares of Sionna Therapeutics during the fourth quarter worth $36,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Sionna Therapeutics during the second quarter worth $44,000.

More Sionna Therapeutics News

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: The stock’s rebound may reflect bargain hunting and short-term volatility following the steep selloff, although no new positive clinical data were reported.
• Neutral Sentiment: Analyst opinion has broadly converged around a more cautious stance. Royal Bank of Canada upgraded SION to “Sector Perform,” while Stifel Nicolaus assigned a “Hold” rating. Royal Bank of Canada upgrade
• Negative Sentiment: Sionna reported that its Phase 2a PreciSION CF trial of lead candidate SION-719 failed to achieve its key endpoint for sweat-chloride reduction. The drug will not advance as an add-on therapy, severely damaging the company’s near-term cystic-fibrosis development prospects. Sionna halts lead cystic fibrosis drug
• Negative Sentiment: The clinical failure erased roughly 90% of SION’s market value and removed a potential competitive threat to Vertex Pharmaceuticals, whose shares benefited from the news. Vertex rises as Sionna trial fails
• Negative Sentiment: Several firms reduced their ratings, including Lifesci Capital and JonesTrading to “Hold,” Wedbush to “Neutral,” Raymond James to “Market Perform,” and BTIG and Guggenheim to lower ratings. These actions signal reduced confidence after the trial result. Wedbush downgrade
• Negative Sentiment: Levi & Korsinsky announced a pending investor investigation into potential securities-law violations related to disclosures that allegedly indicated SION-719 was on track before the failed trial outcome. The investigation adds legal and reputational risk. Sionna investor investigation notice

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.